2021年阿尔茨海默病药物研发进展
Alzheimer's disease drug development pipeline: 2021.
作者信息
Cummings Jeffrey, Lee Garam, Zhong Kate, Fonseca Jorge, Taghva Kazem
机构信息
Chambers-Grundy Center for Transformative Neuroscience Department of Brain Health School of Allied Health Sciences, University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USA.
Biogen Weston Massachusetts USA.
出版信息
Alzheimers Dement (N Y). 2021 May 25;7(1):e12179. doi: 10.1002/trc2.12179. eCollection 2021.
INTRODUCTION
The number of individuals worldwide with Alzheimer's disease (AD) is growing at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs in clinical trials for the treatment of AD.
METHODS
We interrogated ClinicalTrials.gov, the federal registry of clinical trials to identify drugs in trials.
RESULTS
There are 126 agents in 152 trials assessing new therapies for AD: 28 treatments in Phase 3 trials, 74 in Phase 2, and 24 in Phase 1. The majority of drugs in trials (82.5%) target the underlying biology of AD with the intent of disease modification; 10.3% are putative cognitive enhancing agents; and 7.1% are drugs being developed to reduce neuropsychiatric symptoms.
DISCUSSION
This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of AD.
引言
全球患有阿尔茨海默病（AD）的人数正在迅速增长。迫切需要新的治疗方法。我们回顾了目前正在进行的用于治疗AD的临床试验药物管线。
方法
我们查询了美国国立医学图书馆维护的临床试验注册库ClinicalTrials.gov，以识别正在进行试验的药物。
结果
有152项试验中的126种药物在评估AD的新疗法：28种处于3期试验，74种处于2期，24种处于1期。试验中的大多数药物（82.5%）针对AD的潜在生物学机制，旨在改变疾病进程；10.3%是假定的认知增强剂；7.1%是正在开发用于减轻神经精神症状的药物。
讨论
这条药物管线分析表明，目标生物学过程更加多样化，生物标志物使用更加频繁，并且正在探索重新利用的药物以确定其治疗AD的效用。
Zotero 插件